Form 8-K Esperion Therapeutics, For: Oct 18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/8/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- Atlassian results seen as 'game changer' for AI kills software worries
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Esperion Therapeutics (ESPR) PT Lowered to $30 at Cowen
October 19, 2021 6:26 AM EDTCowen analyst Joseph Thome lowered the price target on Esperion Therapeutics (NASDAQ: ESPR) to $30.00 (from $60.00) while maintaining an Outperform rating.
The analyst commented, "ESPR announced organizational changes to conserve cash in a challenging launch environment ahead of the Q1:23 CV Outcomes... More
Credit Suisse Downgrades Esperion Therapeutics (ESPR) to Neutral
October 18, 2021 6:08 PM EDTCredit Suisse analyst Judah Frommer downgraded Esperion Therapeutics (NASDAQ: ESPR) from to Neutral with a price target of $11.00 (from $28.00).
The analyst comments "Following a challenged launch for bempedoic acid during the Covid-19 pandemic, along with administrative complications borne out of preauthorization requirements for many prescriptions, Esperion communicated a shift in strategy to... More
